Tagrix is the generic name of Tagrisso, is licensed only with a doctor's prescription and is used to treat patients with advanced or metastatic non-small cell lung cancer who have the T790M mutation of the epidermal growth factor receptor (EGFR) (NSCLC).
Tagrix is made in Bangladesh by the Beacon Pharma Ltd. manufacturing facility.
Patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC) who have progressed while receiving EGFR tyrosine kinase inhibitor (TKI) therapy or after receiving such treatment, as determined by an approved test, are candidates for treatment with Tagrix.
